{"id":"https://genegraph.clinicalgenome.org/r/2bb68c20-182d-4957-8472-b536daf225abv3.0","type":"EvidenceStrengthAssertion","dc:description":"*MAGI2* was evaluated for evidence supporting and refuting its relationship with autosomal dominant epilepsy. Of note, variation in *MAGI2* has also been described in association with autosomal recessive nephrotic syndrome. Evidence for this gene-disease relationship is not considered here. \n\n*MAGI2* was initially thought to be involved in epilepsy after large deletions including *MAGI2* (and other genes) were reported in individuals with infantile epilepsy (PMIDs: 18565486, 26030165). *MAGI2* was thought to be the causative gene because it has been found to interact with stargazin, a protein that has been associated with epilepsy in mice (PMID: 16870733), and it was the region with the most overlap amongst patients with documented infantile spasms (PMID: 18565486). There have been reports of individuals with deletions at the 7q11.23-7q2.11 locus, where *MAGI2* is located. One individual has a deletion at this locus that spans part of *MAGI2*, but this individual does not have a diagnosis of epilepsy (PMID:18565486). There are also reports of four other individuals with deletions in this region that do not include *MAGI2*, but who have been diagnosed with infantile spasms, suggesting that there is an alternate cause of disease (PMIDs: 21694734, 14636357, 20146355). While some MAGI2 single nucleotide variants have recently been reported in individuals with epilepsy, the genetic testing method used in the paper does not sufficiently rule out other genetic causes of epilepsy, and many variants are present with high allele counts in gnomAD (PMID: 30986657).\n\nFurthermore, when considering experimental evidence, *MAGI2* null mouse models have not been reported to present with epilepsy (PMIDs: 25108225, 27932480). Instead, these mice have renal abnormalities consistent with the phenotypic presentation of patients with biallelic intragenic null frameshift variants. This suggests that the absence of *MAGI2* may cause nephrotic syndrome, rather than epilepsy. \n\nIn summary, the evidence supporting the relationship between *MAGI2* and autosomal dominant epilepsy has been refuted and no valid evidence remains to support the claim. This classification was approved by the ClinGen Epilepsy Gene Curation Expert Panel on October 17, 2023. \n\nThis gene-disease pair was originally evaluated by the ClinGen Epilepsy Gene Curation Expert Panel on June 19, 2018 and was classified as disputed. In September 2021 and July 2023, it underwent minor administrative updates, but evidence was not reevaluated. Evidence was reevaluated on October 17, 2023. As a result of this reevaluation, the classification did change from disputed to refuted due to a continued lack of valid supporting evidence, and the exclusion of all other new evidence (PMIDs: 25497044, 30986657).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/2bb68c20-182d-4957-8472-b536daf225ab","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff","calculatedEvidenceStrength":"NoKnownDiseaseRelationship","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2023-10-17T19:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2023-11-10T20:59:36.426Z","role":"Publisher"}],"curationReasonDescription":"There have been reports of individuals with deletions at the 7q11.23-7q2.11 locus, where MAGI2 is located. However, no single-gene deletions of MAGI2 have been reported in this gene in individuals with epilepsy to date. One individual has a deletion at this locus that spans part of MAGI2, but this individual does not have a diagnosis of epilepsy (PMID:18565486). There are also reports of four other individuals with deletions in this region that do not include MAGI2, but who have been diagnosed with infantile spasms, suggesting that there is an alternate cause of disease (PMIDs: 21694734, 14636357, 20146355). While some MAGI2 single nucleotide variants have recently been reported in individuals with epilepsy, the genetic testing method used in the paper does not sufficiently rule out other genetic causes of epilepsy, and many variants are present with high allele counts in gnomAD (PMID: 30986657). Because there is no valid evidence remaining to support the relationship between MAGI2 and autosomal dominant epilepsy, no new convincing cases have been reported since 2018, and multiple publications (PMIDs: 31056551, 25497044) reported the absence of a connection between MAGI2 and epilepsy, we are refuting this relationship.","curationReasons":["ErrorClarification","RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6ffa7d6-88cf-42ff-9177-d7f5d8e6cd55","type":"EvidenceLine","dc:description":"Many genes are expressed in the human brain. Expression alone does not support a relationship with epilepsy.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7449d0fa-24ba-49b8-a660-4c66838b10e5","type":"Finding","dc:description":"\"We performed coimmunoprecipitation experiments to test whether TARPs interacted with MAGI-2 in vivo in mouse brain (Fig. 4). The anti-TARP antibody coimmunoprecipitated with two prominent MAGI-2 isoforms from wild-type and stargazer cerebral cortex but not from cerebellum or hippocampus from either mouse. These isoforms correspond to MAGI-2 \u0005 and \u0002 based on their sizes. In wild-type cerebral cortex, \u00012, \u00013, and \u00018 were also immunoprecipitated so any of these, or some combination, might be responsible for interacting with MAGI-2.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16870733","rdfs:label":"Expression of MAGI2 in the brain of mice","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4e6d7119-dd39-4920-8a7e-08800fd73532","type":"EvidenceLine","dc:description":"In this interaction, though the authors implicate that the MAGI2 protein may be involved in neuron endo/exocytosis, this doesn't directly implicate the phenotype because they only tested neurons in the retina. Additionally, while this study cites several other studies showing that MAGI2 participates in endocytosis, these studies are out of the scope of this curation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/312ef0ad-f68a-4951-9738-e3221bbeac61","type":"Finding","dc:description":"The authors identified Magi2 (membrane-associated guanylate kinase inverted-2) as a new component of the USH protein interactome, binding to the multifunctional scaffold protein SANS (USH1G). The phosphorylation of an internal PDZ-binding motif in SANS by the protein kinase CK2 was reported to regulate the SANS-Magi2 complex assembly. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24608321","rdfs:label":"USH1G interacts with MAGI2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ab1972dd-d07b-4dbf-81b3-6b6c39e85d3e","type":"EvidenceLine","dc:description":"Though the Stargazin CACNG2 gene has been implicated with intellectual disability in humans (Hamdan, 2010, PMID: 21376300) and epilepsy in mice (Letts, 1998, PMID: 9697694), there does not seem to be enough genetic evidence to consider this relationship as moderate or definitive, and therefore this interaction shouldn't be scored as evidence that MAGI2 has a relationship with epilepsy.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e77cbb7-97aa-4667-bdef-66e6cb490efc","type":"Finding","dc:description":"\"We confirmed that MAGI-2 coimmunoprecipitated with stargazin in vivo from mouse cerebral cortex and used in vitro assays to localize the interaction to the C-terminal -TTPV amino acid motif of stargazin and the PDZ1, PDZ3, and PDZ5 domains of MAGI-2. Expression of stargazin recruited MAGI-2 to cell membranes and cellâ€“ cell contact sites intransfected HEK-293T cells dependent on the presence of the stargazin -TTPV motif. These experiments identify MAGI-2 as a strong candidate for linking TARP/AMPA receptor complexes to a wide range of other postsynaptic molecules and pathways and advance our knowledge of protein interactions at mammalian CNS synapses.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16870733","rdfs:label":"Stargazin interaction with MAGI2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf256ace-78c2-4ea1-8f04-5acd62960045","type":"EvidenceLine","dc:description":"This mouse model supports the evidence indicating that the MAGI2 gene may have a relationship with abnomalities of the renal system as opposed to abnormalities of the central nervous system causing early infantile spasms. \n\nOf note, details about the heterozygous knock-out mice phenotypes were not reported. If it is presumed that infantile spasms result from monoallelic/autosomal dominant variants in MAGI2, phenotypic information about heterozygous knockout mice would be most relevant. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6fb2e633-2a12-4a33-bc0c-bf89408b3914","type":"Finding","dc:description":"Membrane-associated guanylate kinase inverted 2 (MAGI-2) is a tight junction protein in epithelial tissues.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25108225","rdfs:label":"MAGI2 Null mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bafc241b-f32f-4a8b-806d-229a033da1cb","type":"EvidenceLine","dc:description":"This identified a different candidate gene in the locus that was identified to have deletions in the patients with ISS. These individuals did not have a deletionn of the MAGI2 gene and therefore this paper was evidence against the association.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f9599b8-6b7b-4ef5-ac39-4363267beb6e","type":"Finding","dc:description":"The gene YWHAG1 is identified by this paper to be a candidate gene for the cause of the ISS phenotype in the patients. One of the patients has haploinsufficiency of this gene adn they found that the heart was malformed with arrhythmia in the morphant zebrafish. They don't say anything about whether the zebrafish had epilepsy but they do suggest that the protein is critical for development of the nervous system.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20146355","rdfs:label":"YWHAG1","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7d622b88-9c77-47f8-93b1-808517da0cff_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a89e7a1-34fe-4092-ab55-18c666291ff1","type":"EvidenceLine","dc:description":"Allele count of 3585 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a89e7a1-34fe-4092-ab55-18c666291ff1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/1282636f-7f1f-44a0-a516-691a4c020d74","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.2213G>A (p.Arg738Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA153630"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bb93f8a2-a1bc-4540-b0d3-1f15b9e2a381","type":"EvidenceLine","dc:description":"Allele count of 5204 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb93f8a2-a1bc-4540-b0d3-1f15b9e2a381_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/8b7f24ac-0a0a-495d-8652-6765799d879b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.3911G>A (p.Gly1304Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4313355"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7737967c-19cb-486b-8992-e6335f4d1da7","type":"EvidenceLine","dc:description":"Allele count of 26 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7737967c-19cb-486b-8992-e6335f4d1da7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/ec4ac3a8-32c8-46c9-9b43-0b6642fdf91a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.874C>T (p.Pro292Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4314160"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/67cd82d2-bbe8-49c3-b2f7-974f437f63a1","type":"EvidenceLine","dc:description":"Allele count of 951 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67cd82d2-bbe8-49c3-b2f7-974f437f63a1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/62dd1e48-ff91-4b9d-bccc-9b1067065320","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.2723C>G (p.Pro908Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4313683"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b9ecdb02-5724-4adb-9007-967ef1b4657e","type":"EvidenceLine","dc:description":"Allele count of 7 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b9ecdb02-5724-4adb-9007-967ef1b4657e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/f0656827-5d04-41a3-bc98-932399902769","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.2023A>G (p.Thr675Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4313918"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/188e194d-e538-4fc3-b931-bb2897fc2c62","type":"EvidenceLine","dc:description":"Allele count of 36 in gnomAD. Insufficiently robust genetic testing method for phenotype.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/188e194d-e538-4fc3-b931-bb2897fc2c62_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30986657","allele":{"id":"https://genegraph.clinicalgenome.org/r/0d3cb3f2-9f23-4c95-a392-973c23ad937e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012301.4(MAGI2):c.1658G>A (p.Arg553Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4313971"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Refuted","sequence":7189,"specifiedBy":"GeneValidityCriteria9","strengthScore":0,"subject":{"id":"https://genegraph.clinicalgenome.org/r/L9nWZLZ2iDQ","type":"GeneValidityProposition","disease":"obo:MONDO_0005027","gene":"hgnc:18957","modeOfInheritance":"obo:HP_0000006"},"version":"3.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7d622b88-9c77-47f8-93b1-808517da0cff-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}